Retrospective Benchmark · Prospective Tracking Live from May 19, 2026

GaiaLab's retrospective benchmark.
— drug-disease pairs GaiaLab scores highly
have matching ClinicalTrials.gov trials.

When GaiaLab runs its evidence scoring against known disease contexts, it surfaces the drugs that actually went to clinical trials — including emerging therapies like Lecanemab, Lorlatinib, and Adagrasib with trials registered 2022–2026. These are retrospective concordance matches: the trials pre-existed our analyses. Prospective tracking live from May 19, 2026 — every new analysis is timestamped in real time. Separately, semantic matching has surfaced 15 prospective matches (2 genuine off-label repurposing hypotheses + 13 on-label concordance).

—
Unique drug-disease
pairs scored
—
Retrospective concordance
matches (unique pairs)
—
Pairs with completed
ClinicalTrials.gov trial
—
Pairs with positive
trial outcome signal
CT.gov metadata only
—
Days of prospective
tracking (live from
May 19, 2026)
—
Brier score
vs 0.25 no-skill baseline
lower = better calibration
Looking for genuinely prospective predictions?
This page remains the retrospective ClinicalTrials.gov concordance ledger. Frozen forward studies live in the Prospective Registry, with a separate Evidence-After-Lock chronology and public track record.
Prospective Registry → Track Record →
📅
Prospective Tracking Started May 19, 2026

Every new analysis from today is timestamped in real time. When a trial registers on ClinicalTrials.gov after GaiaLab scored that drug-disease pair, it counts as a genuine forward prediction. Return in 30, 60, and 90 days to see prospective predictions accumulate. No cherry-picking — every scored pair is in the ledger.

Prospective tracking active for: 0 days
· All — name-matched ledger matches are retrospective (trial pre-dates our analysis)
Separately, semantic matching surfaced 15 prospective matches ↗ where the prediction pre-dates the trial — but in honest terms, 13 are on-label concordance (the drug is already standard-of-care, so the lead-time isn't foresight) and only 2 are genuine off-label repurposing hypotheses.

Recently Registered Trials Matching Our Benchmark

Trials registered 2022–2026 for drugs GaiaLab scores highly
These trials were registered recently. GaiaLab surfaces these drugs through evidence scoring — independent of trial registration data. All matches in this name-matched ledger are retrospective: the drug-disease pair appeared in our scoring before we checked CT.gov, but the trial itself pre-dates May 2026. (Semantic matching surfaces prospective matches separately — see /new-trials.)
Drug Disease NCT ID Trial Registered Why GaiaLab Scores It
Lecanemab Alzheimer's disease NCT07212062 ↗ Oct 2025 Anti-amyloid mAb; APOE, APP, PSEN panel targets; published Phase 3 efficacy
Lorlatinib Non-small cell lung cancer NCT06893354 ↗ Mar 2025 3rd-gen ALK/ROS1 inhibitor; high CIViC/ChEMBL evidence for EGFR/ALK NSCLC
Carboplatin Triple-negative breast cancer NCT06845319 ↗ Feb 2025 DNA damage repair; BRCA1/TP53 targets; strong mechanistic alignment with TNBC
Gemcitabine Pancreatic cancer NCT06991491 ↗ May 2025 Nucleoside analog; broad oncology evidence across KRAS/TP53 panels
Sotorasib Colorectal cancer NCT05198934 ↗ Jan 2022 KRAS G12C inhibitor + anti-EGFR combo (panitumumab); BRAF/KRAS/NRAS panel; sotorasib FDA-approved for NSCLC, tested here in CRC

What the — Matches Represent

Domain intelligence, not database lookup

The — matches include precision oncology agents, emerging Alzheimer's therapies, targeted AML drugs, and novel KRAS inhibitors — not random concordance. GaiaLab scores these through mechanistic pathway alignment, target overlap, and clinical evidence depth.

Targeted Oncology
Adagrasib · Dabrafenib · Encorafenib
Lorlatinib · Osimertinib · Alectinib
Brigatinib · Selumetinib · Tovorafenib
KRAS · BRAF · ALK · EGFR inhibitors
Alzheimer's Emerging Therapies
Lecanemab · Donanemab
Aducanumab · Gantenerumab
Solanezumab
Anti-amyloid antibodies · APP/APOE/PSEN panels
Precision AML
Gilteritinib · Quizartinib
Midostaurin · Ponatinib
Pacritinib
FLT3 · BCR-ABL · JAK2 targeted agents
Immunotherapy
Atezolizumab · Cetuximab
Amivantamab · Panitumumab
Bevacizumab
PD-L1 · EGFR · VEGF · bispecific agents
🔬

Retrospective Concordance — Transparent Methodology

GaiaLab queries the ClinicalTrials.gov API v2. A drug-disease pair is counted as a concordance match when a registered trial exists for that exact pair. All — matches in this name-matched ledger are retrospective — the trial was registered before our analysis. (A separate semantic-matching layer has surfaced 15 prospective matches, of which only 2 are genuine off-label repurposing hypotheses — the rest are on-label concordance.) Completed trial status does not imply positive outcome.

Methodology →

Prediction Calibration by Confidence Level

—
Trial Match Rate — drug-disease pair appears in ClinicalTrials.gov
Research Direction Rate — matches research direction in literature

Drugs With Most Trial Matches

By ClinicalTrials.gov concordance count (retrospective)

Disease Coverage

—

Full Predictions Ledger

Loading…
Drug Disease Key Targets Trial (NCT) Trial Status Verdict Predicted